Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3189 | Quercetin Prophylaxis Wiki | 0.45 |
| drug2341 | Mesenchymal Stem Cell Wiki | 0.45 |
| drug1873 | IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care. Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug496 | BRII-196 Wiki | 0.45 |
| drug3190 | Quercetin Treatment Wiki | 0.45 |
| drug1876 | Ibrutinib Wiki | 0.32 |
| drug2114 | Leflunomide Wiki | 0.32 |
| drug2181 | Low Dose Radiation Therapy Wiki | 0.32 |
| drug2933 | Placebo Administration Wiki | 0.22 |
| drug4025 | Tocilizumab Wiki | 0.07 |
| drug421 | Azithromycin Wiki | 0.07 |
| drug1775 | Hydroxychloroquine Wiki | 0.04 |
| drug2916 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000741 | Anemia, Aplastic NIH | 0.45 |
| D010265 | Paraproteinemias NIH | 0.45 |
| D008998 | Monoclonal Gammopathy of Undetermined Significance NIH | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008218 | Lymphocytosis NIH | 0.45 |
| D009190 | Myelodysplastic Syndromes NIH | 0.32 |
| D009369 | Neoplasms, NIH | 0.22 |
| D007676 | Kidney Failure, Chronic NIH | 0.17 |
| D003324 | Coronary Artery Disease NIH | 0.15 |
| D008173 | Lung Diseases, Obstructive NIH | 0.12 |
| D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.12 |
| D020521 | Stroke NIH | 0.11 |
| D013577 | Syndrome NIH | 0.04 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.04 |
| D055371 | Acute Lung Injury NIH | 0.04 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.03 |
| D011014 | Pneumonia NIH | 0.02 |
| D007239 | Infection NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100827 | Lymphocytosis HPO | 0.45 |
| HP:0012133 | Erythroid hypoplasia HPO | 0.45 |
| HP:0002863 | Myelodysplasia HPO | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002664 | Neoplasm HPO | 0.22 |
| HP:0001677 | Coronary artery atherosclerosis HPO | 0.15 |
| HP:0006536 | Pulmonary obstruction HPO | 0.12 |
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.12 |
| HP:0001297 | Stroke HPO | 0.11 |
| HP:0002090 | Pneumonia HPO | 0.02 |
Navigate: Correlations HPO
There are 5 clinical trials
This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.
Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.
Measure: 7-day length of invasive mechanical ventilation (MV) Time: Up to 7 daysDescription: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: 30-day mortality rate Time: Up to 30-day after randomizationDescription: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of intensive care (ICU) transfer Time: Up to 2 yearsDescription: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of invasive mechanical ventilation Time: Up to 2 yearsDescription: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of tracheostomy Time: Up to 2 yearsDescription: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test
Measure: Length of ICU stay Time: Up to 2 yearsThis phase III trial compares low dose whole lung radiation therapy to best supportive care plus physicians choice in treating patients with COVID-19 infection. Low dose whole lung radiation therapy may work better than the current best supportive care and physician's choice in improving patients' clinical status, the radiographic appearance of their lungs, or their laboratory blood tests.
Description: Will be measured by improvements on oxygenation need prior to intervention compared with after intervention and/or hospital discharge.
Measure: Time to clinical recovery Time: Up to follow-up day 14 after study startDescription: The rates from both cohort will be reported.
Measure: Freedom from ICU admission Time: Up to follow-up day 14 after study start; This may be extended up to 28 days after preplanned interim analysis.Description: Temperature in degrees (F)
Measure: Temperature Time: Up to follow-up day 14 after study startDescription: Heart rate in beats per minutes
Measure: Heart rate Time: Up to follow-up day 14 after study startDescription: Systolic blood pressure in mm Hg
Measure: Systolic Blood pressure Time: Up to follow-up day 14 after study startDescription: Oxygen saturation in percentage
Measure: Oxygen saturation Time: Up to follow-up day 14 after study startDescription: Oxygen saturation in percentage
Measure: Supplemental oxygenation need Time: Up to follow-up day 14 after study startDescription: Respiratory rate in breaths per minute.
Measure: Respiratory rate Time: Up to follow-up day 14 after study startDescription: Pre and post intervention; Minimum of 3 (poor) to best (15)
Measure: Glasgow Comma Scale from minimum of 3 to maximum of 15. Time: Up to follow-up day 14 after study startDescription: Easter Cooperative Oncology Group (ECOG) Performance Status Scale from 0-5; 0 being best; 5 being dead;
Measure: Performance status Time: Up to follow-up day 14 after study startDescription: Survival in percentage
Measure: Survival Time: Up to follow-up day 14 after study start; This may be extended to 28 days after preplanned interim analysis.Description: Serial chest x-rays categorized using published scale into ordinal ranks 1-5 for SARS.
Measure: Serial chest x-rays severe acute respiratory syndrome (SARS) scoring Time: Up to follow-up day 14 after study start;Description: CT scans with volume of consolidation measured in cubic centimeters.
Measure: Changes on computed tomography (CT) scans pre and post RT Time: Baseline up to follow-up day 14 after study startDescription: C-Reactive Protein in mg/L
Measure: CRP Time: Up to follow-up day 14 after study startDescription: Will be summarized descriptively.
Measure: Serum chemistry + complete blood cell (CBC) with differential Time: Up to follow-up day 14 after study startDescription: pH (no unit)
Measure: Blood gases pH(when available) Time: Up to follow-up day 14 after study startDescription: Albumin in gm/dL
Measure: Albumin Time: Up to follow-up day 14 after study startDescription: Procalcitonin in ng/mL
Measure: Procalcitonin Time: Up to follow-up day 14 after study startDescription: Asparatate Aminotransferase in units/L
Measure: Aspartate aminotransferase (AST) Time: Up to follow-up day 14 after study startDescription: Creatinine in mg/dL
Measure: Creatine kinase Time: Up to follow-up day 14 after study startDescription: Coagulation pathway time in seconds
Measure: Prothrombin time (PT)/partial thromboplastin time (PTT) Time: Up to follow-up day 14 after study startDescription: Troponin-I in ng/mL
Measure: Troponin Time: Up to follow-up day 14 after study startDescription: Lactic Acid in mmol/L
Measure: Lactate Time: Up to follow-up day 14 after study startDescription: B-Natriuretic Peptid in pg/mL
Measure: NT-pBNP (cardiac injury) Time: Up to follow-up day 14 after study startDescription: Gamma-glutamyl transferase in units/L
Measure: Gamma-glutamyl transferase (GGT) Time: Up to follow-up day 14 after study startDescription: Trygliciericdes in mg/dL
Measure: Triglycerides Time: Up to follow-up day 14 after study startDescription: Fibrinogen in mg/dL
Measure: Fibrinogen Time: Up to follow-up day 14 after study startDescription: Will be summarized descriptively.
Measure: Changes in CD8 T cells Time: Up to follow-up day 14 after study startDescription: Will be summarized descriptively.
Measure: Changes in CD4 T cells Time: Up to follow-up day 14 after study startDescription: Will be summarized descriptively.
Measure: Changes in serum antibodies against COVID-19 epitope Time: Up to follow-up day 14 after study startDescription: Lactate Dehydrogenase in units/L
Measure: LDH Time: Up to follow-up day 14 after study startDescription: D-Dimer in ng/mL
Measure: D-Dimer Time: Up to follow-up day 14 after study startDescription: Interleukin-6 in pg/mL
Measure: IL-6 Time: Up to follow-up day 14 after study startDescription: Myoglobin in ng/mL
Measure: Myoglobin Time: Up to follow-up day 14 after study startDescription: Potassium in mmol/L
Measure: Potassium Time: Up to follow-up day 14 after study startDescription: Ferritin in ng/mL
Measure: Ferritin Time: Up to follow-up day 14 after study startDescription: Alanine Aminotransferase in units/L
Measure: ALT Time: Up to follow-up day 14 after study startThis phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. This may reduce the need to be on a ventilator to help with breathing.
Description: Associations between baseline characteristics and the primary endpoint will be evaluated with logistic regression, adjusting for arm. These analyses will be largely descriptive, as a result of a limited sample size.
Measure: Proportion of patients with diminished respiratory failure and death Time: During hospitalization for COVID-19 infection or within 30 days of registrationDescription: Fever-free will be assessed by a temperature of < 100.5 degrees Fahrenheit orally. Will be estimated for each arm using the method of Kaplan-Meier. Medians estimates and/or estimates at specific time points will be provided with 95% confidence intervals.
Measure: Time from study initiation to 48 hours fever-free Time: Up to 14 daysDescription: Will be estimated for each arm using the method of Kaplan-Meier. Medians estimates and/or estimates at specific time points will be provided with 95% confidence intervals.
Measure: Duration of hospitalization Time: Up to 14 daysDescription: Adverse events will be summarized by grade, type, and attribution (regardless of attribution and treatment-related) for each arm.
Measure: Incidence of grade 3 or higher adverse events Time: Up to 12 monthsDescription: The proportion of patients with viral clearance at the time of hospital discharge will be estimated with 95% confidence intervals for each arm.
Measure: At the end of therapy (day 14) Time: Up to 14 daysDescription: Will be estimated for each arm using the method of Kaplan-Meier. Medians estimates and/or estimates at specific time points will be provided with 95% confidence intervals.
Measure: Time to viral clearance Time: Up to 12 monthsDescription: Patients will be followed for up to 12 months or until death or withdrawal of study consent for further follow-up. Following hospitalization, study visits will be telephone or video encounters.
Measure: Survival Time: Up to12 monthsThis phase I/II trial investigates the best dose and side effects of leflunomide and how well it works in treating patients with COVID-19 and a past or present cancer. Leflunomide has been used since the 1990s as a treatment for rheumatoid arthritis. Experiments done with human cells that were given severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing COVID-19, showed that leflunomide was able to reduce the ability of the virus to make copies of itself. The coronavirus uses ribonucleic acid (RNA), a very long molecule that contains genetic information that is like a blueprint for making more copies of itself. Leflunomide inhibits the formation of RNA. The information gained from this study may help researchers to learn whether leflunomide is safe for use in treating patients with COVID-19, and whether it is potentially effective against the disease.
Description: Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study of treatment and reversibility or outcome.
Measure: Incidence of toxicity, graded according to the NCI CTCAE version 5 Time: Up to 28 days after completion of study treatmentDescription: Will be based on the assessment of dose limiting toxicity (DLT).
Measure: Maximum tolerated dose (MTD) (Phase 1) Time: During the 28-day treatment periodDescription: Defined as a >= 2-point change in clinical status from day 1 on a 7-point ordinal scale.
Measure: Clinical activity (Response)(Phase 2) Time: At day 28Description: Defined as time from start of treatment to >= 2 point change in clinical status on a 7 point ordinal scale
Measure: Time to Clinical activity (Response) Time: Up to 28 daysDescription: Defined as time from start of treatment to death from any cause
Measure: Overall Survival Time: Up to 90 daysDescription: Time from start of treatment to peripheral capillary oxygen saturation (SpO2) > 93% on room air
Measure: Oxygen Saturation improvement Time: Up to 90 daysDescription: Time from start of treatment to first negative severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) result assessed by polymerase chain reaction (PCR).
Measure: SARS-CoV-2 resolution Time: Up to 90 daysDescription: Hospitalized within first 90 days following start of treatment assessed as yes/no
Measure: Hospitalization Time: Up to 90 daysDescription: Indication as to whether or not the subject required mechanical ventilation at any time from start of treatment through 90 days post; assessed as yes/no
Measure: Mechanical Ventilation required Time: Up to 90 daysDescription: If the subject required mechanical ventilation, indicate number of days for first occurrence; measured in days.
Measure: Mechanical Ventilation duration Time: Up to 90 daysDescription: Vital status will be reported as yes/no
Measure: Vital status (alive/dead) Time: Up to 90 daysDescription: If vital status is dead, cause of death will be documented.
Measure: Vital status (cause of death) Time: Up to 90 daysDescription: Measured by PCR assay of viral ribonucleic acid (RNA) from nasopharyngeal swab.
Measure: Viral load Time: from start of treatment to 90 daysThis phase I trial investigates the side effects of cord blood-derived mesenchymal stem cells (MSC) in treating patients with COVID-19 infection (COVID-19)-related acute respiratory distress syndrome (ARDS). MSCs are a type of stem cell that can be taken from umbilical cord blood and grown into many different cell types that can be used to treat cancer and other diseases. The MSCs being used for infusion in this trial are collected from healthy, unrelated donors and are stored and grown in a laboratory. Giving MSC infusions may help control the symptoms of ARDS.
Description: Serious adverse events with be comprised of grade 3 or 4 graft versus host disease or death and will be estimated and reported overall and by group, along with 95% confidence intervals.
Measure: Incidence of composite serious adverse events (Pilot) Time: Within 30 days of the first mesenchymal stem cell (MSC) infusionDescription: Will be estimated and reported with 95% confidence intervals.
Measure: Proportion of successfully extubated patients who present intubated on ventilator support (Pilot) Time: Up to day 30 post MSC infusionDescription: Will be estimated and reported with 95% confidence intervals.
Measure: Rate of successful progression to intubation in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Pilot) Time: Up to day 30 post MSC infusionDescription: Will be estimated and reported with 95% confidence intervals.
Measure: Overall survival rate (Pilot) Time: At day 30 post MSC infusionDescription: Will be estimated and reported with 95% confidence intervals.
Measure: Survival rate in patients who present intubated on ventilator support (Pilot) Time: At day 30 post MSC infusionDescription: Will be estimated and reported with 95% confidence intervals.
Measure: Survival rate in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Pilot) Time: At day 30 post MSC infusionDescription: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Measure: Determine the treatment effect on clinical parameters, oxygenation and respiratory parameters Time: Up to day 30 post MSC infusionDescription: All grades of infusion-related adverse events will be summarized by grade and type.
Measure: Incidence of infusion-related adverse events (Pilot) Time: Up to day 30 post MSC infusionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports